ANDA 75807, held by Regcon Holdings. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 75807 (Fluoxetine Hydrochloride), held by Regcon Holdings, was first approved by FDA on Jan 29, 2002, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2002 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Oct 30, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 31, 2006 | Supplement 7Labeling | Approved | None posted |
| Jun 7, 2005 | Supplement 4Labeling | Approved | None posted |
| Jun 7, 2005 | Supplement 5Labeling | Approved | None posted |
| Sep 13, 2004 | Supplement 1Labeling | Approved | None posted |
| Jan 29, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters